The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

John Lilly and the Earth Coincidence Control Office’ from Michael Almereyda and Courtney Stephens, narrated by Chloë Sevigny, debuts at Rotterdam, exploring the life of the utopian neuroscientist.

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

Zepbound, developed by Lilly, is an obesity treatment that received approval in November 2023. In South Korea, it is expected to be released under the product name "Mounjaro" in May. Eli Lilly is ...

The new guidance includes revenues of about $3.5 billion for Mounjaro and $1.9 billion for Zepbound and represents 45% growth from the year-ago quarter. Eli Lilly also cut its revenue guidance for ...

Eli Lilly (NYSE ... and the market was less than enthusiastic. Lilly reported lower-than-expected U.S. sales growth for its GLP-1 diabetes drug Mounjaro and its weight-loss offshoot Zepbound.

Eli Lilly reported a revenue of $13.5 billion, missing the consensus estimate of around $14 billion. The shortfall was attributed to weaker-than-expected sales from its Mounjaro and Zepbound ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare ... including its top GLP-1 drugs, Mounjaro ($3.1 billion) and Zepbound ($1.3 billion). Late last year, regulators approved Zepbound as ...